To read the full story, subscribe or sign in.

PD arrest made? Voyager rounds up cohorts, strikes operation’s brains via trial

Dec. 9, 2016

Voyager Therapeutics Inc. has a Parkinson’s disease gene therapy that could last “essentially for as long as the patient lives, but at least 15 or 20 years,” CEO Steven Paul told BioWorld Today, commenting on phase Ib results with VY-AADC01.

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for May 8, 2026.

Rendering of a key measles protein targeted by neutralizing human antibodies

First measles treatment advances as vaccination rates drop

BioWorld

Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...

Infensa Bioscience identifies new ASIC blockers

BioWorld Science

Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.

Art concept for inflammation in the intestines

Kymera’s IRF5 degrader shows potential in IBD treatment

BioWorld Science

At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...

Hantavirus is ‘sentinel’ more than acute pandemic threat

BioWorld

News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...